GB002 Inc.

Address: 3115 Merryfield Row Suite 120

Sponsor Overview

assignment

Specializations

Pulmonary Arterial Hypertension

GB002 Inc. focuses its clinical research on pulmonary arterial hypertension, with studies centered on WHO Group 1 pulmonary hypertension and the management of disease burden in patients receiving background PAH therapy.

Exercise capacity
Long-term safety
Tolerability

The sponsor’s trial portfolio reflects sustained interest in inhaled treatment approaches for PAH, including ongoing evaluation of treatment durability and clinical benefit in a multi-country research network.

Inhaled Therapy for Cardiopulmonary Disease

The company’s research activity is concentrated on orally inhaled treatment strategies for cardiopulmonary disease, with attention to therapies designed for chronic use in patients with pulmonary vascular disorders.

Oral inhalation
Chronic treatment maintenance
Adjunctive disease-specific medication

Current studies examine how inhaled therapy can be integrated with established PAH treatment regimens across active research sites in multiple countries.

Safety and Tolerability Research

A major area of interest for GB002 Inc. is the assessment of long-term safety and tolerability in people treated for pulmonary arterial hypertension, with continued follow-up of inhaled therapy in routine clinical contexts.

Long-term exposure
Safety monitoring
Treatment persistence

These studies support ongoing evaluation of treatment suitability for patients requiring prolonged management of PAH.

Trial Name	Country	Status
Evaluation of Seralutinib Efficacy and Safety in Pulmonary Arterial Hypertension: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial	Austria Belgium Czechia Denmark France Germany Greece Ireland Italy Latvia Lithuania Poland Portugal Romania Spain The Netherlands	Not Recruiting
Long-term Safety and Efficacy Evaluation of Inhaled Seralutinib in Pulmonary Arterial Hypertension: An Open-label Extension Study	Austria Belgium Czechia Denmark France Germany Greece Ireland Italy Latvia Lithuania Poland Portugal Romania Spain The Netherlands	Not Recruiting
Long-term Safety and Efficacy Evaluation of Inhaled Seralutinib in WHO Group 1 Pulmonary Arterial Hypertension	Czechia Germany Spain	Not Recruiting